Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)

COVID-19 Clinical Trial

— SABER-C  

Official title:

Pilot and Randomized, Controlled Studies to Assess Stool Frequency of COVID + Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol): SABER-C and Lite-SABER-C (Specific Administration of Bismuth for Early Recovery of COVID-19)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04811339
• Other study ID #: SABER-C 20.0636
• Status: Completed
• Phase: Phase 4
• Start date: October 27, 2020
• Est. completion date: August 15, 2021

Study information

• Verified date: February 2023
• Source: University of Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Center for Disease Control (CDC) and World Health Organization (WHO) have deemed the COVID-19 virus a global pandemic of unprecedented severity in modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and has now caused upwards of 1million deaths and over 6 million infections globally. Currently, the estimated global economic impact is over 5 Trillion dollars. Understanding the host response to pathogens, specifically the cellular and humoral responses, has played an important role in new non-antibiotic therapies. Bismuth subsalicylate (Pepto-Bismol) has a potential role in the clearance and/or recurrence of enteric viral infections.

Description:

Readily available over-the-counter (OTC) medication for symptomatic relief and appropriate oral hydration can be health saving measures of great convenience for those affected by enteric bacterial and viral infections. BSS is a non-proprietary monograph product that is available in the USA and abroad, over-the-counter (OTC). Of all OTC medications for traveller's diarrhea (TD), bismuth subsalicylate (BSS) has the greatest antimicrobial activity against pathogenic bacteria .BSS has also exhibited significant inhibition on viral invasion of host cells and viral efficacy. Both BSS and bismuth oxychloride (BiOCl, which is formed in the stomach after ingestion of BSS) at low concentration (0.004-0.13mg/mL) significantly reduced norovirus (NoV) RNA levels, suggesting an in vivo antiviral mechanism. BSS has also been shown to have antiviral activity since it inhibited replication of 4 strains of rotavirus in tissue culture cells and caused a dose-dependent reduction in the growth of several enteric viruses.

Historically, BSS has been indicated and effectively used for the treatment of TD or enteric infection, mainly when vomiting occurs. Although the safety and efficacy of BSS is well known, some of the research done with BSS resides within the industry and have not been published. We have recently completed an extensive meta-analysis using unpublished clinical studies regarding BSS safety and efficacy. Meta-analyses of randomized controlled clinical trials were performed with studies specifically designed to capture prevention of manifestation and relief of diarrhea.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: August 15, 2021
• Est. primary completion date: August 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

To be eligible to participate in the study, patients must meet the following criteria:

Ability to provide written or remote informed consent (telephone and DocuSign) Ability to comply with study requirements, Men or women 18 to 85 years of age, inclusive Current diagnosis of an initial occurrence of non-severe, non-complicated COV+ infection as defined by:

• Presence COVID-19 in the saliva using point of care (POC) Qualitative real time - polymerase chain reaction (QRT- PCR) assay.

• Management in an outpatient (i.e., non-hospital) or inpatient setting NOT on a ventilator.

• Alert and awake

• Able to chew the study drug completely.

• Women should fulfill one of the following criteria:

• Answer in the affirmative that "they are not or could not be pregnant"

• Post-menopausal; either amenorrhea =12 months or follicle stimulating hormone >20 mIU/mL (milli-International units)

• Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation.

• Women of childbearing potential participating in heterosexual sexual relations must be willing to use adequate contraception from Screening through the 21 Day visit, per Section 10.2.

Standard of care COVID-19 treatment is acceptable.

Exclusion Criteria:

Patients with any of the following will be excluded from admission into the study:

• Existence of an intra-abdominal abscess, enteric fistula, or symptomatic bowel obstruction

• History of allergy to salicylates.

• History of short gut syndrome, active ulcer or recent history of GI bleeding or melena.

• Systemic chemotherapy for the treatment of cancer during the 60 days prior to consent or planned during the study

• Active use of remdesivir.

• vaccination for COVID within 30 days.

• Current use of drugs that control diarrhea or affect peristalsis (e.g., loperamide. Opiates can be used in hospitalized patients and with outpatients if they are prescribed to a patient), or any anticipated use during the study

• Active drug, chemical, or alcohol dependency as determined by Investigator through history or urine toxicology screen

• Enrollment in any other investigational drug or device study known to interfere with Pepto bismol (bismuth subsalicylate) within the GI tract, within 30 days prior to Randomization (Day 1) or within 5 half-lives of the last dose of the previous investigational compound, whichever is longer. Vaccines are not exclusionary as they do not interfere with the mechanism of the study drug.

• Severe acute illness unrelated to COVID-19

• Pregnant, breast-feeding, or considering becoming pregnant during the study

• Planned hospitalization or surgery during the study

• Any medical, psychiatric, social, or other circumstances that may interfere with study compliance, completion, or accurate assessment of study outcomes

Related Conditions & MeSH terms

• COVID-19
• Diarrhea

Intervention

Drug:
• Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable
Pepto bismol (bismuth subsalicylate)

Other:
• Placebo oral tablet without BSS
Placebo Tablet made by P & G to contain everything except active ingredient ( BSS)

Locations

Country	Name	City	State
United States	University of Louisville	Louisville	Kentucky

Sponsors (2)

Lead Sponsor	Collaborator
University of Cincinnati	Procter and Gamble

Country where clinical trial is conducted

United States, 

References & Publications (2)

Brum JM, Gibb RD, Ramsey DL, Balan G, Yacyshyn BR. Systematic Review and Meta-Analyses Assessment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea. Dig Dis Sci. 2021 Jul;66(7):2323-2335. doi: 10.1007/s10620-020-06509-7. Epub 2020 Aug 8. — View Citation

Yacyshyn MB, Collins J, Chua M, Siegwald A, Yacyshyn S, Briones-Pryor V, Yacyshyn B. Feasibility study of Bismuth Subsalicylate (BSS) as an addition to standard of care for COVID-19 therapy. Curr Ther Res Clin Exp. 2022;96:100667. doi: 10.1016/j.curtheres.2022.100667. Epub 2022 Mar 30. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth	Number of bowel movements recorded over the 3 day study. Baseline (BL) /day1 + Day 2 + Day 3	3 days
Secondary	Salivary SARS-CoV2 Day 3 Status Using Reverse-transcription Loop-mediated Isothermal Amplification (RT-LAMP)	Salivary SARS-CoV2 measured daily. The final outcome is SARS-CoV2 status on day 3. Clearance of SARS-CoV2 ( a negative salivary SARS-CoV2 RT-LAMP test). or Remained SARS-CoV2+ ( a positive salivary SARS-CoV2. RT-LAMP test)	Day 3 - or 48 hours after starting BSS